Form 4: Mirum CEO Peetz Reports Insider Stock Transactions

Mirum Pharmaceuticals CEO Christopher Peetz reported the vesting of performance restricted stock units and subsequent sale of shares to cover tax obligations.

Summary

• Christopher Peetz, CEO and Director of Mirum Pharmaceuticals, Inc. (MIRM), reported transactions involving the company's common stock.
• On March 15, 2026, Peetz acquired 25,000 shares of common stock upon the vesting of performance restricted stock units.
• On the same date, March 15, 2026, Peetz acquired an additional 50,000 shares of common stock from the vesting of other performance restricted stock units.
• On March 16, 2026, Peetz sold 40,985 shares of common stock at a price of $91.9779 per share.
• The sale of shares was conducted to cover tax withholding obligations associated with the vesting of the performance restricted stock units.
• Following these transactions, Peetz directly holds 194,309 shares of common stock and indirectly holds 187,500 shares through The Peetz Family Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions are routine for executive compensation and tax management, not indicative of a significant shift in company fundamentals or insider sentiment.

Positives

• Vesting of 75,000 performance restricted stock units suggests that performance targets tied to these awards were met, indicating positive company performance.

Negatives

• A sale of 40,985 shares by the CEO, even for tax purposes, slightly reduces direct insider ownership.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for insider transactions, providing transparency into executive stock ownership changes. The sale to cover tax obligations is a common practice following equity award vesting and does not typically signal a change in management's outlook on the company's prospects.

Comparison to Industry Standards

• The practice of selling shares to cover tax withholding obligations upon the vesting of equity awards is a common and standard procedure for executives across publicly traded companies, including those in the biotechnology and pharmaceutical sectors like Mirum Pharmaceuticals.

Corporate Governance

Related Party Transactions

• Indirect ownership of 187,500 shares of common stock is held through The Peetz Family Trust.

Stakeholder Impact

• Shareholders: Provides transparency into executive stock ownership and compensation practices. The sale for tax purposes is a common occurrence and generally not seen as a negative signal regarding company prospects.

Next Steps

• The remaining 1/3 of the second tranche of Performance Restricted Stock Units (25,000 shares) are scheduled to vest on March 15, 2027.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation and tax obligations. It does not provide new information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The vesting of PRSUs indicates past performance targets were met, which is generally positive, but the subsequent tax-related sale is a standard practice. Therefore, a 'hold' recommendation is appropriate as this filing does not present a compelling reason to alter an existing investment thesis.

Keywords

Mirum Pharmaceuticals, MIRM, Christopher Peetz, insider trading, Form 4, stock transactions, CEO, director, equity, restricted stock units, RSU, stock sale, tax withholding